Back to search results

Advancing Care Coordination for Complex Cancer Survivors

This study is looking at a new approach called Primary Care Connect (PC2) to improve care for people who have had certain cancers (breast, prostate, bladder, or endometrial) and also have a higher risk for heart problems. PC2 involves patient education, better use of electronic medical records, and clear communication between your cancer care team and your primary care doctor. The goal is to see if PC2 helps manage your risk of cardiovascular disease (CVD) better than usual care. You might be able to join if you are an adult, were diagnosed with one of these cancers in the last 6 months, are being treated with the goal of cure at Rutgers Cancer Institute of New Jersey, and have at least one risk factor for CVD. The study is currently unclear on its recruitment status.

Study design
This is an interventional study planning to enroll 266 participants. It is a randomized clinical trial, meaning participants will be assigned by chance to either receive Primary Care Connect or usual care.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your connection with your primary care provider will be measured from the time you join the study until 18 months after you enroll.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06834204

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

Enrolling by Invitation
NAAges 18+InterventionalHealth services
Rutgers, The State University of New Jersey
~266 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:PC2: Primary Care Connect

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Connected Care-Continuity with Primary Care Provider
Measured over From the time of enrollment to 18-months post enrollment.

Conditions

Cancer
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Bladder Cancer
Prostate Cancer (Adenocarcinoma)
Endometrial Cancer
Hypertension
Hyperlipidemia (E.G., Hypercholesterolemia)
Diabetes Mellitus

Explore related trials

Bladder CarcinomaBreast CarcinomaEndometrial CarcinomaProstate Carcinoma

NCT06834204

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Rutgers Cancer Institute

    New Brunswick, New Jerseyno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Denalee M O'Malley, PhD, MSW · PRINCIPAL_INVESTIGATOR · Rutgers, The State University of New Jersey

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

diagnosed with any of the following cancers \[Stage I-III\]: breast, prostate, urinary bladder, and endometrial in the past 6 months;
being treated for cancer with curative intent;
had initial patient visit at the cancer center in the last 3 months;
are being treated for cancer with curative intent at the Rutgers Cancer Institute of New Jersey
have ≥1 CVD risk factor (hypertension, hyperlipidemia or type II diabetes) prior to cancer diagnosis that requires medication management;
currently receiving care from a primary care provider;
Speak English or Spanish

Exclusion

had myocardial infarction or stroke within the previous 1 year;
have heart failure with an ejection fraction \<30%; (3) have stage IV-V chronic kidney disease (eGFR \<30);
or do not speak English or Spanish. Patients whose cancer progresses to metastatic disease during the course of the 18-month trial will be allowed to continue to participate unless they voluntarily withdraw

What this trial measures

  • Connected Care-Continuity with Primary Care ProviderFrom the time of enrollment to 18-months post enrollment.

    Three primary care visits focused on chronic disease management from time of enrollment to 18-months post-enrollment.